Drugs / AGMB-447
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06181370 | Dec 2023 → Apr 2026 | idiopathic pulmonary fibrosis | Agomab Therapeutics NV | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | Agomab Spain S.L.U. | Regulatory Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis agomab.com ↗
Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB -447, to Agomab . |
| 2026-01-08 | Agomab Spain S.L.U. | Results Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort agomab.com ↗
Agomab Therapeutics NV (‘Agomab’), a clinical -stage biopharmaceutical company focused on fibrosis, today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants. |
| 2024-06-06 | Agomab Spain S.L.U. | Regulatory Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis agomab.com ↗
Agomab Therapeutics NV (‘Agomab’) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AGMB-447, its inhaled, small molecule inhibitor of ALK5. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-14 | Agomab Spain S.L.U. | Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study agomab.com ↗ |
| 2026-03-26 | Agomab Spain S.L.U. | Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis agomab.com ↗ |
| 2026-01-08 | Agomab Spain S.L.U. | Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort agomab.com ↗ |
| 2024-06-06 | Agomab Spain S.L.U. | Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis agomab.com ↗ |
| 2023-12-14 | Agomab Spain S.L.U. | Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis agomab.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGMB-447 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06181370 ↗ |
| Route | Inhaled | “AGMB-447 administered via nebulizer” NCT06181370 ↗ |